Followers | 64 |
Posts | 23541 |
Boards Moderated | 0 |
Alias Born | 11/23/2016 |
Sunday, June 26, 2022 11:13:14 AM
Evidently Anavex trials are all designed for a long stretched out suck and see approach, not at all to fail quickly. How many investors have been here since 2014 or before, every year saying this is the year of Anavex?
Take the PDD P2 trial that ended up labelled a Proof of Concept trial now 2 years later still waiting for the next trial to start.
The very small P2a AD trial on which more soup has cooked for coming up to 6 years.
The two very small adult Rett trials, that ended up having 6 patients in a suck it and see PK/PD pre-trial and again in AVATAR, this time with 3 patients doing a suck and see first.
Its been a suck and see, adjust and keep on going for the longest time - absolute no sign of boldly trying to fail and get it over with or go big and get it done.
Thus far forever close, but no cigar yet and looking as good as ever...
No complaining at all, there could well be sense in the Missling approach - we will eventually soon'ish know for sure maybe this year or the next.
Ninety something WGT scores are for after a confirmatory trial win and before dosh is being made. Win dosh ticking in then close to 100% WGT but not touching, as something can always still go wrong with biotech and medicine.
Recent AVXL News
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:04:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:06 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:31:07 PM
- Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/07/2024 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:01:34 PM
- Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans • GlobeNewswire Inc. • 01/24/2024 12:30:00 PM
- Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 01/16/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 01:00:34 AM
- Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 12:30:00 PM
- Anavex Life Sciences Provides an Update on Rett Syndrome Program • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome • GlobeNewswire Inc. • 12/20/2023 12:30:00 PM
- Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease • GlobeNewswire Inc. • 12/19/2023 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/27/2023 09:30:41 PM
- Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Monday’s Wall Street Highlights: Walmart, Disney, Lloyds Banking, Mitsui Financial, HSBC, and more • IH Market News • 11/27/2023 11:29:25 AM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM